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Abstract objectives The WHO recommends inclusion of post-exposure chemoprophylaxis with single-dose
rifampicin in national leprosy control programmes. The objective was to estimate the cost of leprosy
services at primary care level in two different public-health settings.
methods Ingredient-based costing was performed in eight primary health centres (PHCs)
purposively selected in the Union Territory of Dadra and Nagar Haveli (DNH) and the Umbergaon
block of Valsad district, Gujarat, India. All costs were bootstrapped, and to estimate the variation in
total cost under uncertainty, a univariate sensitivity analysis was performed.
results The mean annual cost of providing leprosy services was USD 29 072 in the DNH PHC
(95% CI: 22 125–36 020) and USD 11 082 in Umbergaon (95% CI: 8334–13 830). The single
largest cost component was human resources: 79% in DNH and 83% in Umbergaon. The unit cost
for screening the contact of a leprosy patient was USD 1 in DNH (95% CI: 0.8–1.2) and USD 0.3 in
Umbergaon (95% CI: 0.2–0.4). In DNH, the unit cost of delivering single-dose of rifampicin (SDR)
as chemoprophylaxis for contacts was USD 2.9 (95% CI: 2.5–3.7).
conclusions The setting with an enhanced public-health financing system invests more in leprosy
services than a setting with fewer financial resources. In terms of leprosy visits, the enhanced public-
health system is hardly more expensive than the non-enhanced public-health system. The unit cost of
contact screening is not high, favouring its sustainability in the programme.
keywords leprosy, cost analysis, health systems, primary care
Introduction
Leprosy is a chronic infectious disease caused by
Mycobacterium leprae. While the first outward sign is
usually discoloured painless skin patches, a delay in diag-
nosis can lead to complications including physical disabil-
ity [1]. Many challenges are associated with leprosy
infection. First, the transmission mechanism is unclear
[2], and the incubation period with active transmission is
long [3]. Second, those affected are vulnerable to co-
infections and mental health problems [4, 5]. Third, the
stigma caused by leprosy is more severe than that of
other stigma-causing diseases such as epilepsy and tuber-
culosis [6]; stigma not only isolates socially but also
restricts employment opportunities [7, 8]. Fourth, disabil-
ity is reported mainly in the productive age group and
interrupts employment, sometimes lifelong [9]. Finally,
the afflicted population is mainly poor [4, 10], and the
cost of treatment imposes a high burden on households
[11].
Sixty per cent of the 210 758 new leprosy cases diag-
nosed worldwide in 2015 were diagnosed in India [12].
New case detection has remained almost stagnant in the
past 9 years, indicating uninterrupted transmission [12,
13]. Although the Indian National Leprosy Eradication
Program (NLEP) showed an annual new case detection
rate (ANCDR) of 9.71 per 100 000 and a prevalence rate
of 0.66 per 10 000 population in 2015–16 [13], national
average rates are not representative of leprosy-affected
pockets. In 80 districts (12% of all districts in India), the
ANCDR per 100 000 population was over 20 new cases,
and 22 districts (3% of all districts) reported a rate
higher than 50 new cases [13]. After the declaration of
prevalence-based elimination in 2005, the Indian program
was criticised for being passive and missing new cases
[14, 15]. Therefore, in 2016, the NLEP started a door-to-
door Leprosy Case Detection Campaign (LCDC), cover-
ing 149 districts across 19 states [16, 17]. Since incep-
tion, LCDC claimed to detect more than 34 000 new
cases under NLEP (source: Central Leprosy Division,
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India), but this figure still lies below the number of esti-
mated hidden cases [14, 15].
As leprosy recently gained a significant political com-
mitment from the Government of India, it is now back
on the agenda of the Ministry of Health and Family Wel-
fare [18]. The 2017 parliamentary budget speech also
included a commitment to eradicate leprosy by 2018 [19]
(a target that seems unrealistic given the present epidemi-
ological level) [15]. However, as the NLEP is in the pro-
cess of testing feasible strategies for interrupting
transmission of M. leprae, economic analysis, particularly
costing estimates, is important to guide the decisions that
aim to improve financial efficiency [20].
As costing estimates at primary-care level in leprosy
are scarce [21], our study aimed to estimate the cost of
leprosy services at primary care level in two different
public-health settings. Because health care in India is
organised at the provincial level, individual public-health
settings differ in factors such as funding, staffing and
infrastructure, which are linked directly to the cost of ser-
vices and indirectly to service coverage. To gain an over-
view of the possible variation in costs, we therefore
examined two different public-health settings. The pur-
pose of this study was to mainly provide cost estimates
that can aid financial planning of a scale-up and assessing
the cost-effectiveness of leprosy control activities, includ-
ing post-exposure prophylaxis with single-dose of rifam-
picin (SDR).
Methods
Study sites
Data were collected in the Union Territory of Dadra and
Nagar Haveli (DNH) and the adjoining Umbergaon
block of Valsad district, Gujarat, each a tribal area with
a similar demographic and socioeconomic structure
(Table 1). A block is a district subdivision administrative
unit. As each area is rated as highly endemic for leprosy,
its leprosy epidemiology is also comparable [13]. The
public-health systems are nonetheless different, because
DNH operates directly under the federal government and
receives a higher central budgetary assistance per capita
for overall and health funding alike [22, 23]. Relative to
Umbergaon, DNH’s public-health system is enhanced in
terms of its available infrastructure (Table 1), human
resources (Table S1), and service delivery coverage
(Table S2) [24]. Due to these factors, leprosy patients’
out-of-pocket expenditure on primary care in DNH is
lower [25].
In both areas, leprosy services are integrated into the
local public healthcare delivery system. Besides the
routine leprosy programme activities, an annual LCDC
campaign has also been performed since 2016 in DNH
and Umbergaon. Since March 2015, the LPEP program is
ongoing in DNH, but not in Umbergaon. The DNH was
selected for LPEP due to the highest new case detection
rate (NCDR), child case rate and prevalence rate in the
year 2014–15 [26]. Moreover, DNH had a better infras-
tructure and human resources in place to experiment a
pilot project. The LPEP program—whose details are
available in the published protocol [27]—is intended to
assess the feasibility and impact of contact tracing and
administration of single-dose rifampicin (SDR) to asymp-
tomatic contacts of leprosy cases [27]. The contact was
defined as someone who has had prolonged or regular
contact with an index case. The efficacy of SDR was
Table 1 Comparison of Dadra and Nagar Haveli and Umber-
gaon with regard to demography, epidemiology, socioeconomic
factors and public-health facilities
Indicators DNH Umbergaon
Demographic and socioeconomic indicators (census 2011)
Number of households (HH) 76 121 54 814
Population 343 709 261 204
Rural population 53.2% 68.7%
Females (per 1000 males) 774 933
Literacy 76.2% 69.5%
Schedule tribes† 51.9% 51.3%
Total working population 45.7% 40.4%
Epidemiology (2015–2016)
Leprosy-screened population 388 613 371 731
New cases detected 425 287
NCDR (per 100 000
per year)
109.3 77.2
New child cases
(age <14 years)
23.2% 16.0%
New female cases 57.8% 61.6%
Prevalence/Registered
patient rate (per
10 000 per year)
6.7 3.8
Grade II disability
in new cases
3.3% 2.4%
PB/MB ratio 2.7 3.1
Public-health Infrastructure (2015–2016)
Area (sq. km) 491 343
Primary health centres (PHC) 15 10
Sub-centres 50 64
Average population
screened for leprosy by
health centre
25 907 37 173
MB, multibacillary; NCDR, new case detection rate; PB, pau-
cibacillary; Source: Tiwari et al. 2017 [30].
†The Scheduled Castes (SCs) and Scheduled Tribes (STs) are offi-
cially designated groups of historically disadvantaged indigenous
people in India.
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already established [28] and found to have a protective
effect of 57% [29]. The operational alignment of LPEP
and NLEP is described elsewhere [30]. By including
leprosy patients’ neighbours and social contacts, the
LPEP has intensified contact tracing, improved screening
sensitivity and broadened the coverage of contact exami-
nation.
Cost data collection and analysis
When designing the study, we referred to the ‘WHO
Guide to Cost-Effectiveness Analysis’ and ‘Drum-
mond’s check-list for assessing economic evaluations’
[31, 32], taking the perspective of the health system.
The first step was to identify financial sources that
contribute to leprosy service delivery: the local public-
health system, the NLEP and LPEP (donor funds for
DNH only). The data related to sampled primary
health centres (PHCs) were spread at three levels: dis-
trict (which included only NLEP and LPEP expendi-
tures), PHCs and sub-centre (Figure 1). The sub-
centres, which are the most peripheral health units,
are managed by paramedical staff and cater mainly
for preventive care, with some curative services for
minor ailments [20]. We did not collect data on
leprosy costs at international, national or state levels
as we only focused on the primary care level.
The cost data were collected from June to October
2016, for eight PHCs (four PHCs at each study site), pur-
posively selected on the basis of the leprosy prevalence of
2014–15, that is, a mix of low, medium and high leprosy
endemicity (Table S3). The bottom–up ingredient-based
approach was applied to costing [33]. Costs were cate-
gorised as follows: capital costs, including building,
equipment and other consumables, that had lasted for
more than 1 year; and recurrent costs, that is, staff sal-
aries, reimbursements for leprosy schemes, monitoring,
repeated training, drugs, consumables and overheads such
as water and electricity bills, that had been incurred in
the previous year (June 2015 to May 2016). After facility
assessment (to list all assets), records were cross-checked
to determine the quantity of assets consumed with their
purchasing price. For the assets, prices data were not
available; we used data from other state government’s
pricing lists or open market rates. To record total work-
ing durations and the proportion of time allocated to
leprosy services, staff were interviewed on the basis of a
semi-structured questionnaire. This proportion of time
allocated to leprosy was multiplied with the correspond-
ing remuneration to derive HR cost. The annual cost of
Levels
District
NLEP
Program management,
Monitoring and
supervision, Training,
Data management and
research
Service delivery
management, Data
validation and reporting,
Diagnosis confirmation,
Case management,
Rehabilitation aid
Contact tracing
Screening, Recording
and reporting, Follow-up,
MDT and aid distribution,
IEC
SDR (only in DNH)
LPEP (only in DNH)
NLEP
LPEP (only in DNH)
Local public-health,
PHC
Sub-center
Program
Contributors
Main
Activities
Figure 1 Data collection levels and corresponding leprosy control activities in DNH and Umbergaon.
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buildings was estimated by multiplying the government
rental rates by the roof-covered surface area of the facili-
ties. Equipment was annualised based on its useful life at
a discount rate of 3% [31]. Shared costs other than HR
were apportioned on the bases of leprosy prevalence, that
is, the number of patients on the treatment register
(Table S3).
To review treatment progress, leprosy patients should
ideally be examined every month [34]. During analysis,
patients on monthly multidrug therapy (MDT)—the stan-
dard leprosy treatment—were aggregated to an annual
proxy of leprosy visits, which, as a proportion of annual
general outpatient department (OPD) visits, served as
leprosy-proportion allocation (Table S4) [32]. The term
proxy is used because visits can be paid either by patients
or by health staff; usually, patients visit PHCs irregularly
and receive monthly services such as MDT and a general
check-up (treatment progress review) at their doorstep by
field staff [25]. Patients tend to visit health facilities only
for more severe medical conditions. It was also the case
that PHCs had data only on general OPD visits, which
were not classified into leprosy-related visits.
We surveyed one sub-centre in each sampled PHC in
DNH and Umbergaon and considered it as a standard
example (Table S5). The cost of a standard example was
multiplied by the number of sub-centres under the respec-
tive PHC. The sub-centres received medicines and con-
sumables from their respective PHCs, which are covered
under PHC costing and therefore excluded in the stan-
dard example to avoid double counting.
Using India GDP deflators, all prices were converted to
the 2015 (base year) price. The annual costs were col-
lected for the complete 2015–2016 financial year. US dol-
lars (USD) were converted at an exchange rate of INR 67
[35]. Unit costs were derived by dividing the cost by the
corresponding service output.
To overcome the small sample size, all costs were boot-
strapped with 999 iterations to estimate robust point esti-
mates and confidence intervals. We performed univariate
sensitivity analysis with a first scenario of a 25% fluctua-
tion in all cost components (upper and lower side of base
estimate). In the second scenario, human resources and
drug costs fluctuated by 80% on the lower side and by
100% on the upper side, and the rest of the components
remained as in the first scenario (25% fluctuated on
either side). In the third scenario, total programmatic
(Local public-health, NLEP and LPEP) contributions fluc-
tuated 25% on either side. The fluctuation percentages
were referred from other published literature, specific to
primary health care setting in India [20].
The database was created in Microsoft Excel, cost
analysis was conducted in SPSS 21, and the sensitivity
analysis was conducted using SensIt (TreePlan) in Micro-
soft Excel.
Results
Profiling PHCs
A total of eight PHCs were sampled (four at each site),
covering the leprosy-related cost from district to sub-cen-
tre levels. The DNH had six sub-centres, and Umbergaon
had nine sub-centres attached per sampled PHC. In
DNH, a health centre was staffed by a mean of 47 peo-
ple; in Umbergaon, the mean was 26. Mean leprosy-
related staff (i.e., completely or partially engaged) was 31
in DNH and 23 in Umbergaon, including Accredited
Social Health Activists (ASHAs), who are involved
actively in NLEP.
The Umbergaon had to cater a higher mean catchment
population (40 298) than DNH (27 237) with less staff.
Conversely, mean general outpatient visits were higher in
DNH (31 318) than in Umbergaon (22 021). The mean
number of leprosy visits served by DNH (480) was twice
as high as that served in Umbergaon (218). In 2015–
2016, 53% more new cases were detected in DNH than
in Umbergaon. On average, 29 042 contacts of leprosy
patients were registered at a PHC in DNH (including
those registered in the LPEP program); in Umbergaon,
38 475 contacts were registered. These covered contacts
were close to the total catchment population, as they had
been registered largely during the LCDC, which had had
a high coverage (Table 2). The mean number of contacts
registered per PHC under LPEP was 2500, and 114 Index
cases.
Annual costs
The mean annual cost of providing leprosy services was
USD 29 072 (95% CI: 22 125–36 020) in DNH and
USD 11 082 (95% CI: 8334–13 830) in Umbergaon. HR
costs were the single largest component (79% in DNH
and 83% in Umbergaon). The cost of drugs (including
MDT and SDR) was 10% in DNH and 11% in Umber-
gaon and was followed by overhead costs of 8% in DNH
and 4% in Umbergaon.
Table 3 breaks down the annual mean cost of leprosy
services under various components. Unlike the propor-
tional cost distributions, the cost estimates differed
between the two areas. In Umbergaon, HR costs were
60% lower than in DNH, drug costs were 61% lower
and overhead costs were 80% lower. In DNH, drug costs
also included the rifampicin (SDR) used in the LPEP pro-
gram.
4 © 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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The cost of MDT was dependent on treatment dura-
tion according to the type of leprosy (PB or MB). The
number of MB cases was higher in DNH than in Umber-
gaon (Table 1). Of all components, expenditure on con-
sumables was the smallest and can be considered as a
part of expenditure on drugs or curative care. As capital
costs, buildings and equipment together were also rela-
tively low: 2.7% in DNH and 2.6% in Umbergaon
(Table 3).
Table 4 shows the annual mean cost of leprosy pro-
gramme components, at district and sub-centre level. The
local public-health system’s cost was 51% in DNH and
67% in Umbergaon, which was highest, compared to
NLEP and LPEP (as other cost contributors). The NLEP
expenditure was 31% in DNH and 33% in Umbergaon,
while LPEP accounted for an additional 18% in DNH.
The local public-health system cost in Umbergaon was
50% less than DNH; the difference being statistically sig-
nificant. The NLEP cost in Umbergaon was 59% less
than in DNH (Table 4).
Unit cost
The unit cost was derived as a ratio of mean total annual
cost (Table 3 or 4) and service output (Table 2) in that
year (Table S4). Separately, the LPEP unit cost was
derived from the LPEP program cost only. The unit cost
for screening a leprosy patient’s contact was USD 1
(95% CI: 0.8–1.2) in DNH (3G/(2G+2H)) and USD 0.3
(95% CI: 0.2–0.4) in Umbergaon (3G/2G). The number
of contacts registered and screened in Umbergaon was
32% higher than in DNH (Table 2). The cost per new
case detected and managed was USD 531 (95% CI:
486.7–575.3) in DNH and USD 312 (95% CI: 292.4–
331.9) in Umbergaon (3G/2F). The unit cost per leprosy
visit was USD 60.5 (95% CI: 59.5–61.6) in DNH and
USD 50.9 (95% CI: 50.0–51.8) in Umbergaon (3G/2E).
Under LPEP, the cost per person screened in DNH was
USD 2.1(4C/2H). Of the total number of contacts
screened (10 000) under LPEP, 7314 contacts received
SDR (n = 4 PHC DNH) at a unit cost of USD 2.9 (95%
CI: 2.5–3.7).
Sensitivity analysis
Univariate sensitivity analysis was performed to esti-
mate the difference between the expected value and the
observed value of total annual cost, based on the
uncertainty of a specific cost component. The scenarios
were (1) 25% fluctuation in all cost components, (2)
human resource and drug costs fluctuated by 80% on
lower side and 100% on upper side, (3) total program-
matic contributions fluctuating 25% on either side. The
total annual cost of the leprosy programme was most
sensitive to HR; in DNH, this was 97.2% for scenario
1 and 98.2% for scenario 2, against 98.1% for sce-
nario 1 and 98.3% for scenario 2 in Umbergaon. In
scenario 1, a fluctuation of 25% in HR cost resulted
in 19.2% and 20.6% fluctuation in the total cost of
DNH and Umbergaon, respectively. In scenario 2, a
reduction in 80% in HR cost resulted in 62.7% and
66% reduction in the total cost of DNH and
Table 2 Profile of sampled Primary Health Centres in Dadra Nagar Haveli and Umbergaon in 2015–2016
S. no. Characteristics (2015–2016)
DNH (n = 4) Umbergaon (n = 4)
Mean Range Mean Range
2A Catchment population 27 237 20 644–30 800 40 298 33 500–47 665
2B Human resources† 47 36–69 26 14–45
2C Leprosy human resources‡ 31 20–57 23 17–43
2D General outpatient visits§ 31 318 24 400–45 670 22 021 17 280–28 300
2E Leprosy visits¶ 480 80–800 218 95–376
2F New cases detected 55 5–88 36 14–67
2G Contacts registered under NLEP 26 542 20 644–30 800 38 475 32 561–44 032
2H Contacts registered under LPEP 2500 200–4166 NA
The mean refers to an average value per PHC. NA, not applicable.
†Human resources (medical and non-medical staff, and active volunteers) deployed at or below PHC level. This does not include NLEP
and LPEP staff.
‡Human resources (medical and non-medical staff, and active volunteers) engaged in leprosy services (exclusive or shared). This does
not include NLEP and LPEP staff at district level.
§The general outpatient visits are the number of visits, not persons.
¶Leprosy visits calculated on the basis of leprosy prevalence.
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Umbergaon. Furthermore, a 100% increase in HR cost
resulted in 78.4% and 82.5% increase in the total cost
of DNH and Umbergaon.
Drugs were the next most influential component for
total cost (DNH: 1.7% for scenario 1 and 2; Umbergaon:
1.6% for scenario 1 and 2). There was little variation in
the percentage between the two scenarios for HR and
drugs in both areas, meaning that the total cost had a
low threshold level with respect to HR and the change in
the cost of drugs. Changing the cost of building, equip-
ment and consumables had a negligible impact on the
total cost. In scenario 3, the total cost was most sensitive
to the local public-health system cost (66.4% in DNH
and 79.9% in Umbergaon), followed by NLEP (25.2% in
DNH and 20.1% in Umbergaon). A fluctuation of 25%
in the local public-health system and NLEP cost resulted
into fluctuation of 12.7% and 7.8% in the total cost of
DNH, respectively, and 16.7% and 8.3% in Umbergaon.
The LPEP total cost for DNH had a swing of 8.4% with
respect to the induced variation (Figures S1 and S2).
Changing the LPEP cost by 25% resulted into a fluctua-
tion of 4.5% in the total cost.
Discussion
By quantifying expenditures, this study provides a
detailed cost analysis of leprosy primary care in two dif-
ferent public-health settings in India. The results inform
about the allocative efficiency which is important for pol-
icy planning, aiming at the improvement of the leprosy
control programme. As leprosy is a chronic disease whose
treatment duration ranges from 6 to 12 months, primary
care is an important aspect of disease management. PHCs
are the nodal points for public-health care and managing
programmes at the grass-roots level.
Indian leprosy services are now largely integrated into
the general public-health system [30]. Previously, the
country’s National Leprosy Eradication Program (NLEP)
was fully vertical, providing separate human resources
and infrastructure to leprosy services, which later merged
into the general health care. Nonetheless, NLEP still pro-
vides limited vertical support, especially to highly ende-
mic areas, mainly for the following: non-capital
expenditure on diagnostics; disability (rehabilitation,
reconstructive surgeries and prosthetics); Information
Education and Communications (IEC); additional human
resources; and research. It is also the case that a network
of non-governmental organisations (NGOs) supports var-
ious activities in line with the NLEP, including the imple-
mentation of pilot projects. The three main financial
contributors in leprosy elimination are therefore the local
public-health system, NLEP and NGOs. At district level,
these financial contributors have their programme man-
agement teams which support local public-health system
(PHCs and sub-centres) to provide leprosy services.
Although the two neighbouring study areas are compa-
rable with regard to demographic and socioeconomic fac-
tors, DNH had better resources and detected more leprosy
cases than Umbergaon. The number of new cases depends
not only on endemicity levels but also on active case-find-
ing inputs, which are resource intensive. DNH is more
active in case finding because it has an additional research
project, LPEP, which facilitates active case detection and
contact examination. However, LCDC also contributes to
new case detection (in both areas), but the contact exami-
nation is more thorough in LPEP because it requires ineligi-
ble individuals to be excluded from taking single-dose
rifampicin. Furthermore, the leprosy case-detection cam-
paigns (LCDC) are implemented in a periodic and rapid
(campaign) mode, reaching almost the full population
within a short period (1–2 months per campaign), whereas
LPEP is a continuous 3-year project. As a result, LCDC
covers a higher number of contacts than LPEP.
The mean annual cost of providing leprosy services
was USD 29 072 in DNH and USD 11 082 in Umber-
gaon. The higher PHC cost in DNH was due mainly to
the additional cost of LPEP and to a higher proportion
allocation (Table S4). The higher HR cost in DNH was
mainly due to the higher time spent on leprosy (reported)
by staff and also higher remuneration scale. However,
when accounted for output (leprosy visit), the percentage
difference between the costs of DNH and Umbergaon fell
dramatically. The percentage difference in the total mean
costs was 90%, whereas mean costs per leprosy visit
were only 17% different between DNH and Umbergaon
(Table 3). This means that the higher cost in DNH was
related to more productivity. Next, the total cost of the
NLEP was low in Umbergaon because it is a block whose
resources are shared with rest of the Valsad district. The
percentage difference in the mean NLEP costs was 84%,
whereas NLEP costs per leprosy visit were only 10.6%
different between DNH and Umbergaon. Interestingly,
the local public-health cost per leprosy visit was cheaper
by USD 3.2 in DNH than Umbergaon. As exclusive pub-
lic contribution, the aggregated unit cost (per visit) of
Local public-health and NLEP was still USD 1.2 cheaper
in DNH than Umbergaon. Certainly, in the short run,
LPEP masked the savings in DNH, but as an investment
in prevention, it can still be cost-effective in the long run
(Table S6). Moreover, DNH investment in active case
finding leads to early detection and prevention of new
cases. In future, this will also save cost (opportunity) of
other government programmes such as poverty eradica-
tion, malnutrition and disability support. Additionally,
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out-of-pocket expenditure on leprosy by households will
also be saved in the long run. Our study only focused on
the health system cost, but we recommend exploring
opportunity costs, as there are not many data available,
and required to measure the economic burden of leprosy.
In both DNH (79%) and Umbergaon (83%), HR was
the highest cost element. These high HR costs are in line
with similar studies [20]. Capital cost, in contrast, turned
out to be one of the lowest cost elements: 2.7% in DNH
and 2.6% in Umbergaon. This high HR cost is due to the
fact that national programme at primary care level is a
field-driven public-health programme that provides ser-
vices close to the community. The implementation of
such programmes needs higher investment in HR rather
than in fixed infrastructure (Table S7). Patients also pre-
fer to visit health facilities only for essential curative care
such as acute co-morbidity or leprosy reactions, and
remain non-regular for routine health check-ups. The
afflicted population is mainly poor, and indirect costs
such as wage loss and transportation are a disincentive
for them to pay health-centre visits [25]. The same study
informed that the out-of-pocket expenditure due to
leprosy was lower in DNH than Umbergaon [25]. If
aligned with our study results, then we can infer that an
enhanced health system is comparatively costly, particu-
larly due to the investment in prevention, but that it also
reduces the out-of-pocket expenditure burden on the
households.
At micro level, we also observed that the low endemic
PHCs are not necessarily relatively cheap, mainly due to
fixed costs such as building and equipment, and partially
due to monthly recurrent salary cost.
The local public-health system is the backbone of
leprosy service delivery. The cost of local public-health
system was the highest (51% in DNH and 67% in
Umbergaon), followed by NLEP and LPEP. Next, the
unit costs can be used to estimate the budget by applying
it to the desired level of coverage, but they are not the
indicator for efficiency, therefore should not be inter-
preted as cost-effectiveness of programmes. Moreover, all
unit costs are derivatives of the same overall programme
cost and coverage (process indicators). A more realistic
approach to determining financial efficiency would be to
compare costs with impact indicators using an appropri-
ate time horizon [31]. Usually, when an infectious disease
programme approaches elimination, it becomes more
resource intensive, but, if it possible to eliminate or eradi-
cate the disease, is still considered worthwhile [36].
Our results can provide a basis for budgeting and
financing. Due to the increased political commitment, the
funds allocation for PEP should be not a problem, but
timely flow of funds is a possible financial issue. More
budget for HR means new recruitment, which is a lengthy
process due to governmental regulations. This can lead to
under spending in the initial years and adversely affect the
prospective budgets for PEP. More HR also means more
training; therefore, the general training budgets should
also be revised accordingly. In general, there is a shortage
of cost evidence on leprosy elimination for policy and
planning [21]. To the best of our knowledge, this is the
first comprehensive costing study to take a public-health-
system perspective on leprosy primary care in India. Two
of only three studies to present some costing results were
based on hospitalisation and not on primary care. The
third study, which focused on leprosy case-detection
methods in Nigeria [37], was relevant, but, unlike our
study, also included hospital costs. Another cost-effective-
ness study from Bangladesh presented MDT treatment
programme costs, with and without post-exposure pro-
phylaxis (SDR) [38]. Although—in line with our results—
both the Nigerian and Bangladeshi studies reported HR
cost as the largest component, the actual costs were not
comparable due to the differences in epidemiology, unit
of analysis and scope of the study. Another difference is
that our study focused on primary care, whereas the other
two were designed to evaluate specific activities of leprosy
control. An another costing study on the PHCs (all dis-
eases) of North Indian states, also mentioned HR cost as
the single largest component [20].
A limitation of our method is that our purposive selec-
tion of PHCs to assure representation of low- and high-
performing PHCs may lead to a selection bias thus may
not be representative of the actual distribution of low-,
medium- and high-performing PHC in the areas. This, in
turn, may lead to a deviation in cost estimates if extrapo-
lated to full district/Union Territory or province. The cost
difference between the two public-health settings indi-
cates further cost variation within India as a whole. The
random sampling would either not be a suitable approach
due to very small number of PHCs in the selected areas.
The effect of small sample size of PHCs was minimised
by the bootstrapping method. As another limitation, HR
time allocation was based on self-reporting rather than
on observation, which would have been a better
approach. Next, the NLEP and LPEP cost data were only
available for full district level. To break down the NLEP
and LPEP costs for sampled PHCs, we used the unit cost
per new cases on the assumption that new case detection
solely depends on active case-finding efforts and pumped
resources. In reality, new case detection also depends on
epidemiology, socioeconomic and environmental factors.
However, as the two areas were close with regard to epi-
demiologic and socioeconomic characteristics, we believe
that this risk was minimal in our study. The
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environmental factors were also fairly similar: the two
areas adjoin, are both very small and have no great geo-
graphical differences. As a strength, we used an appropri-
ate costing method and our collection of primary data
for a complete year to minimise any seasonal variations.
We conclude that, due to differences in public-health
system financing and structure, the annual leprosy cost at
primary care level varies even between areas of compara-
ble epidemiology. Our study shows that a setting with an
enhanced public-health financing system invests more in
leprosy services and prevention than one with fewer
financial resources. The enhanced public-health system
overall appears costly, but in terms of productivity, it no
longer remains expensive. Additionally, it also facilitates
reduction in out-of-pocket expenditure among house-
holds. Therefore, we recommend investment in the health
system for prevention and increased access to services,
which will promote early detection and transmission
interruption. According to public-health norms in India,
more resources are needed to cover the population at
risk, therefore these costs should also be seen as an input
that will strengthen the overall health system.
Both systems invested mainly in human resources. In
both the areas, the investment in human resources trans-
lates into active outreach programmes, particularly con-
tact screening. The high investment in HR is essential to
follow the global WHO leprosy guidelines sincerely [39].
We found that post-exposure prophylaxis as addition
to the control programme is resource intensive. However,
once post-exposure prophylaxis has been implemented in
a routine setting, the costs are expected to fall. The
WHO has recently recommended to use SDR for leprosy
prevention, which will trigger scale-up of post-exposure
prophylaxis [39]. Our results can immediately guide the
fiscal planning during scale-up in India, and SDR role out
in other countries after considering the local economies.
The relatively low unit cost of contact screening favours
its sustainability in the programme; however, this does
not mean that contact tracing should be avoided even if
costly. In general, leprosy work is facing financial con-
straint since the global declaration of leprosy elimination.
These results are promising for advocacy and fundraising,
especially in support of SDR. The unit costs are of much
interest for funding agencies to reimburse on case bases
and to plan a flexible investment with a measurable value
of return.
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